StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Calquence (acalabrutinib) — Worldwide YoY actual by Quarter

Calquence (acalabrutinib) — Worldwide YoY actual (%) (%)

QuarterlyAnnual

AstraZeneca Calquence (acalabrutinib) — Worldwide YoY actual: 17.0% in Q2 2026, up 7.0 pts from a year earlier.

Latest, Q2 2026
17.0%
Period ended Jun 30, 2026
Change on a year earlier
+7.0 pts
10.0% in Q2 2025
History
18 quarters
Since Q1 2022
Sources
18
Documents cited below

Where the Q2 2026 figure comes from

“|| Calquence | | 1,022 | | 17 | | 16 | | 687 | | 18 | | 67 | | 36 | | 30 | | 225 | | 13 | | 9 | | 43 | | 3 | | 3”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCalquence (acalabrutinib) — Worldwide YoY actual (%) (%)Year on yearSource
Q2 2026Jun 30, 202617.0%+7.0 ptsForm 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 202621.0%+15.0 ptsForm 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 202520.0%0.0 ptsForm 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 202513.0%-11.0 ptsForm 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 202510.0%-11.0 ptsForm 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 20256.0%-29.0 ptsForm 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 202420.0%+5.0 ptsForm 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 202424.0%+8.0 ptsForm 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 202421.0%-13.0 ptsForm 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 202435.0%+7.0 ptsForm 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 202315.0%-34.0 ptsForm 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 202316.0%-44.0 ptsForm 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 202334.0%-40.0 ptsForm 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 202328.0%-70.0 ptsForm 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 202249.0%–Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 202260.0%–Form 6-K FY2022Q3 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Calquence (acalabrutinib) — Worldwide YoY actual (%), quarterly Q1 2022–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-calquence-world-act-yoy

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.